In addition, the detection of the biomarker triplet, Aβ42, T-Tau and p-Tau-181 in cerebrospinal fluid (CSF) [4,5], is currently the gold standard for neurochemical-based diagnosis, employed to discriminate AD from other dementia subtypes. Here, MAPT is linked to dementia.